Psychopharmacology and Psychiatry Updates SERT Gene Testing: Separating Hype from Evidence
6 snips
Feb 10, 2026 Chris Aiken, psychiatrist and editor who reviews pharmacogenetic literature, breaks down SERT (SLC6A4) testing and its link to SSRI response. He explains alleles, theoretical mechanisms, and why pharmacodynamic predictions are unreliable. He reviews meta-analyses, population differences, stress-related claims, and offers practical advice on interpreting test results in clinic.
AI Snips
Chapters
Transcript
Episode notes
Patient Example: Monica's Genetic Report
- Monica, a 29-year-old with longstanding depression, had multiple SSRI failures and a genetic test claiming an SS SERT variant explained her poor response.
- The podcast raises the question whether that genetic result should guide treatment decisions.
Pharmacodynamic Tests Often Unreliable
- Pharmacodynamic genes like SLC6A4 seem promising but have proven unreliable in trials for predicting drug response.
- A single gene's effect can vary with environment and interacting genes, limiting clinical utility.
Biology vs Evidence: S Allele's Weak Predictive Power
- The serotonin transporter gene (SLC6A4) has short (S) and long (L) alleles, with SS associated with fewer transporters.
- Despite a plausible mechanism, most meta-analyses fail to show SS predicts poor SSRI response broadly.